Tele No.011-23236965
Fax.No.011-23236973

F. No. IND/CT/22/000003
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

18 FEB 2022

To,

M/s Intas Pharmaceuticals Ltd
Corporate House: Near Sola Bridge, S. G. Highway, Thaltej,
Ahmedabad – 380054, Gujarat, INDIA

Subject: Application for permission to conduct a Phase II trial entitled "An Open-Label, Multicenter, Non-Randomized, Dose-Escalation, Phase 2 Study to Evaluate Safety and Efficacy of Intravesical SN-38 Lipid Suspension in Patients with Non-Muscle Invasive Bladder Cancer"- reg.

Sir,

With reference to your online application no. IND/CT04/FF/2022/30354 dated 04.02.2022 on Sugam portal; please find enclosed herewith the permission in **Form CT-06, No. CT/ND/06/2022** to conduct the subject mentioned clinical trial under the provisions of **New Drugs and Clinical Trials Rules, 2019** granted based on evaluation in consultation with Subject Expert Committee (SEC) for IND proposals.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

(Dr. V. G. Somani)
Central Licensing Authority

Condition of permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of

receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licensing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

(xix) It may kindly be noted that merely granting permission to conduct clinical trial study with the drug doesn't convey or imply that based on Clinical Trial data generated with the drug; permission to market this drug will automatically be granted to you.

(xx) The study should be termed as Phase I.

(xxi) Inclusion criteria should be modified to include patients who have already been treated with radiotherapy, chemotherapy and surgery.

(xxii) After completion of 1st dose cohort (40mg/50ml), the report should be presented before the committee, for proceeding to the next dose (60mg/50ml).

(xxiii) Accordingly, revised protocol should be submitted to CDSCO, before initiation of the study.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby M/s Intas Pharmaceuticals Ltd, Corporate House: Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad – 380054, Gujarat, INDIA to conduct clinical trial of an Investigational New Drug as per **Protocol No.0451-21 Version: 01 dated 12.01.2022** in the below mentioned clinical trial sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:	SN-38 Lipid Suspension 20mg/ vial
Therapeutic class:	Inhibitor of Topoisomerase-I
Dosage form:	Injection
Composition:	**SN-38 Lipid Suspension for injection20mg/ vial** Each vial contains : SN-38 .....20mg Excipients .....q.s **Diluent for SN-38 Lipid Suspension for injection 10 ml/ vial** Each ml contains: Lactic Acid IP.....0.817 mg Water for Injection IP .....q.s
Indications:	Proposed for Non-Muscle Invasive Bladder Cancer

Details of clinical trial sites-

Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
1.	Dr. Bhushan Tapiram Nemade Nav sanjeevani Hospital (sankalp Speciality Healthcare Pvt Ltd) Plot No-8, Motkari Nagar, Behind Tupsakhare Lawns, Tidke Colony, Mumbai naka, Nasik-422002, Maharashtra, India	Nav sanjeevani Hospital Ethics Committee c/o Navsanjeevani Hospital (sankalp Speciality Healthcare Pvt Ltd) Plot No-8, Motkari Nagar, Behind Tupsakhare Lawns, Tidke Colony, Mumbai naka, Nasik-422002, Maharashtra, India **ECR/1036/Inst/MH/2018/RR-2021**
2.	Dr. Rajnish Vasant Nagarkar HCG Manavata Cancer Centre, Behind Shivang Auto, Mumbai Naka, Nashik-422002, Maharashtra, India 422002	Manavata Clinical Research Institute Ethics Committee, Behind Shivang Auto, Mumbai Naka, Nashik-422002, Maharashtra, India **ECR/500/Inst/MH/2013-RR-20**
3.	Dr. Rajendra singh Sujan singh Arora Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, 52/B, Shankar Nagar, Main Road, Amravati, 444605 Maharashtra, India	Amravati Ethics Committee, 52/B, Shankar Nagar, Main Road, Amravati 444606, Maharashtra India **ECR/432/Inst/MH/2013/RR-19**

4.	Dr. Pramod Kumar Singh J.K Cancer Institute, GSVM Medical College, Swaroop Nagar, Kanpur-208002, UP, India	Ethics Committee, GSVM Medical college, Principal Office, GSVM Medical college, Kanpur-208002, U.P. India **ECR/680/Inst/UP/2014/RR-20**
5.	Dr. K Velavan Erode Cancer Centre, 1/393 Velavan Nagar, Perundurai road, thindal, Erode- 638012	Institutional Ethics Committee, Erode cancer Centre, 1/393 velavan Nagar, Thindal, Erode-638012 **ECR/319/Inst/TN/2013/RR-19**
6.	Dr. Bhalchandra Dattatreya Kashyapi, Jehangir Clinical Development Centre Pvt. Ltd., Jehangir Hospital Premises, 32 Sassoon Road, Pune-411001	Ethics Committee Jehangir Clinical Development Centre Pvt. Ltd, Jehangir Clinical Development Centre Pvt Ltd, Jehangir Hospital Premises, 32 Sassoon Road, Pune-411001. **ECR/352/Inst/MH/2013/RR-19**
7.	Dr. Seema Devi State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna	Institutional Ethics Committee, Indira Gandhi Institute of Medical Science, Sheikhpura, Patna-800014, India **ECR/640/Inst/BR/2014/RR-20**

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

(Dr. V. G. Somani)
Central Licensing Authority
Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

New Delhi
Date: .....

18 FEB 2022